
Jasper Therapeutics (JSPR) Stock Forecast & Price Target
Jasper Therapeutics (JSPR) Analyst Ratings
Bulls say
Jasper Therapeutics Inc is positioned favorably within the biotechnology sector due to its innovative focus on hematopoietic stem cell therapies and the development of safer conditioning agents. The company has demonstrated a compelling efficacy profile, with a notable 89% complete response (CR) rate observed in clinical trials, highlighting the potential effectiveness of its treatments. Additionally, Jasper's briquilimab is distinguished by its shorter half-life, which could enhance its therapeutic applications compared to competition, suggesting a robust pipeline that may drive future growth.
Bears say
Jasper Therapeutics Inc has faced significant setbacks, including a nearly 5% decline in stock price, attributed to an investigation into a faulty drug lot for briquilimab, which has also led to a pause in the ETESIAN trial for asthma. Additionally, the company raised $30 million through common stock and pre-funded warrants, suggesting potential liquidity challenges amidst ongoing operational issues. The reduction of the price target from $20 to $7 further reflects a negative outlook, underscoring concerns about the company's current financial health and future growth prospects.
This aggregate rating is based on analysts' research of Jasper Therapeutics and is not a guaranteed prediction by Public.com or investment advice.
Jasper Therapeutics (JSPR) Analyst Forecast & Price Prediction
Start investing in Jasper Therapeutics (JSPR)
Order type
Buy in
Order amount
Est. shares
0 shares